The Motley Fool. DATE Thursday, Apr 24, 2025 Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. CALL PARTICIPANTS Rob Davis: Chairman and Chief ...

Merck maintained its 2025 full-year revenue guidance of $64.1 billion to $65.6 billion, representing 1% to 3% growth excluding foreign exchange impacts. EPS guidance was adjusted to $8.82 to $8.97, ...

The effects of COVID-19 continue to reverberate in the cancer risk factors of Americans, a new American Cancer Society study ...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Although the company lowered its full-year outlook for adjusted earnings per share to between $8.82 and $8.97 from between $8.88 and $9.03, that was only because the new guidance included an expected ...

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s ...

On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against ...

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

Doses of imported nine-valent human papillomavirus (HPV) vaccine were administered to male recipients in central ...

United States-based global pharmaceutical company MSD said on Monday that China's National Medical Products Administration has approved the use of multiple new indications of Gardasil®9, its ...

Biopharma giant MSD has received approval for its nine-valent HPV (human papillomavirus) vaccine for use in males aged ...